Telomir Pharmaceuticals (TELO) executive compensation, 2026 proxy

Erez Aminov, Chairman and CEO, was paid $4.9M in 2025, down 36% from $7.6M the year before.

Filed
July 28, 2026
Annual meeting
September 11, 2026
Pay year
2025
Named executives
5
CEO total pay
$4.9M-36% vs prior year
CEO pay in equity
94%$4.6M in awards
CEO 2025 total
$4.88MDown from $7.63M in 2024
CEO option award
$3.744MGranted May 27, 2025
CEO stock award
$840,000Vested fully on grant date
CEO 2026 salary
$500,000Effective January 1, 2026
Option repricing
$1.30Effective May 21, 2026
Mushak monthly pay
$6,000Fractional CFO consulting compensation

How Aminov was paid

$4.9M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary6%Stock awards17%Option awards77%All other compensation0%

Named executive officers

ExecutiveTotal
Erez AminovChairman and CEO$4,880,350
Alan WeichselbaumFormer CFO, Treasurer and Secretary$139,750
Michelle YanezFormer CFO, Treasurer, and Secretary$106,869
Christopher ChapmanFormer Chairman and CEO—
Nathen FuentesFormer CFO, Treasurer, and Secretary—

What changed and why

  • $4.88M$4.88 million: CEO Erez Aminov's 2025 total compensation, down from $7.63 million in 2024.
  • $3.744M$3.744 million: Aminov's 2025 option award, alongside an $840,000 restricted stock unit award.
  • $500K$500,000: Aminov's annual base salary effective January 1, 2026, up from $275,000.
  • $6,000$6,000 monthly: fractional CFO Andriy Mushak's consulting compensation under his one-year agreement.
  • $1.30$1.30 per share: Aminov's option exercise price after the May 2026 repricing.
  • No retirement plans: The company does not currently maintain employee retirement plans.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.